Jump to content

Clouding of consciousness

From Wikipedia, the free encyclopedia
"Brain fog" redirects here; not to be confused with Brain fag or Mild cognitive impairment.

Clouding of consciousness, also called brain fog or mental fog,[1][2] occurs when a person is conscious but slightly less wakeful or aware than normal.[3] The term "brain fog" is used to represent a subjective condition of perceived cognitive impairment. It is defined as "a phenomenon of fluctuating states of perceived cognitive dysfunction that could have implications in the functional application of cognitive skills in people's participation in daily activities".[4] They are less aware of time and their surroundings, and find it difficult to pay attention.[3] People describe this subjective sensation as their mind being "foggy".[5]

Background

[edit]

Clouding of consciousness denotes a less severe state of cognitive impairment than outright delirium. As more abject alteration of consciousness is recognized, physicians may describe patients as in a "confusional state" or delirious, "obtunded", "stuporous", or, in the severest cases, "comatose".[6]

Feature of delirium

[edit]

The term clouding of consciousness has always denoted the main pathogenetic feature of delirium since physician Georg Greiner[7] pioneered the term (Verdunkelung des Bewusstseins) in 1817.[8] The Diagnostic and Statistical Manual of Mental Disorders (DSM) has historically used the term in its definition of delirium.[9] The DSM-III-R and the DSM-IV replaced "clouding of consciousness" with "disturbance of consciousness" to make it easier to operationalize, but it is still fundamentally the same thing.[10] Clouding of consciousness may be less severe than delirium on a spectrum of abnormal consciousness.[3][11][12] Clouding of consciousness may be synonymous with subsyndromal delirium.[13]

Subsyndromal delirium differs from normal delirium by being overall less severe, lacking acuteness in onset and duration, having a relatively stable sleep-wake cycle, and having relatively stable motor alterations.[14] Subsyndromal delirium's significant clinical features are inattention, thought process abnormalities, comprehension abnormalities, and language abnormalities.[14] Delirium's full clinical manifestations may never be reached.[13] Among intensive care unit patients, subsyndromal subjects were as likely to survive as patients with a Delirium Screening Checklist score of 0, but required extended care at rates greater than 0-scoring patients (although lower rates than those with full ICU delirium)[13] and had a decreased post-discharge level of functional independence compared to the general population.[14]

In clinical practice, no standard test is exclusive and specific; therefore, diagnosis depends on the physician's subjective impression. The DSM-IV-TR instructs clinicians to code subsyndromal delirium presentations under the miscellaneous category "cognitive disorder not otherwise specified".[15]

Psychopathology

[edit]

The cerebral cortex and the hippocampus are known to play a critical role in the presentation of brain fog in specific settings. The cerebral cortex, the brain's outermost layer, attached to the cerebrum, is responsible for more advanced processes, such as thought, information recall, maintained wakefulness, and consciousness. The hippocampus, deep within the brain's temporal lobe, organizes, stores, and retrieves information within it, converting memory from short-term to long. It plays a crucial role in enhancing spatial and verbal memory. The cerebral cortex and hippocampus work together to organize and add timing to multiple unconscious brain processes, turning them into a continuous and coherent flow of conscious experience.[16]

Disrupting circadian regulation interferes with neural activation and hippocampus memory processing, reducing thought clarity and alertness and causing confusion. Dysfunction in the hippocampus may limit awareness and make forming cohesive thoughts difficult, resulting in cognitive lapses. These irregularities collectively cause what is known as "brain fog" or clouded consciousness.[citation needed]

The prefrontal cortex (PFC), in the anterior part of the frontal lobe, helps to regulate thought, feeling, and objective-based behavior. It is the final[clarification needed] brain region that undergoes myelination, a mechanism by which insulating myelin sheaths form surrounding axons to improve the rapidity and efficacy of communication between neurons via brain networks.[clarification needed][citation needed]

Research has found that higher cognitive function requires coordinated interaction between the PFC and posterior cortical regions. These posterior areas provide the sensory and perceptual content of conscious experience, whereas the PFC facilitates the executive processes that organize, regulate, and keep that content in awareness. The specific aspects of consciousness correspond to precise patterns of activation within posterior cortical regions, while the PFC helps structure and integrate those activations into coherent thought.[17]

Wake-sleep regulation and neuronal disinhibition

[edit]

Consciousness was historically believed to be a product of the whole of activity in the cerebral hemispheres. But the conscious state is not altered by injury to one hemisphere, "except if the size of [a brain lesion] affects other cortical areas or the diencephalon" or if the lesion is exceptionally large.[6][18] 1916 research by Romanian-Viennese neurologist Constantin von Economo found that specific regions of the brain (the midbrain and diencephalon) targeted by encephalitis lethargica (sleeping sickness) produced alterations in wake-sleep regulation.[6][19] He identified a site at the junction of the brainstem and forebrain where lesions produced prolonged sleepiness, as well as a site that included the anterior hypothalamus where, conversely, lesions produced prolonged insomnia.[19] Based on his observation of patients experiencing lethargy who all had lesions at the junction between these two regions (an area that included the posterior lateral hypothalamus), Von Economo proposed "an ascending arousal system originating in the brainstem that kept the forebrain awake", suggesting that narcolepsy was caused by its dysfunction.[19] This supports the modern notion that distinct segments of the central nervous system are critical for consciousness.[6]

The conceptual model of clouding of consciousness in psychopathology is that of a part of the brain regulating the "overall level" of consciousness, which is responsible for awareness of oneself and of the environment.[3][20] Various etiologies disturb this regulating part of the brain, which in turn disturbs the "overall level" of consciousness.[21] This system of a sort of general activation of consciousness is called "arousal" or "wakefulness".[20]

Altered cognition

[edit]

Clouding of consciousness is not necessarily accompanied by drowsiness.[22] Patients may not be sleepy yet still have clouded consciousness (disorder of wakefulness).[23] Paradoxically, affected individuals say they are "awake but, in another way, not".[24] Lipowski points out that decreased "wakefulness" as used here is not exactly synonymous with drowsiness. One is a stage on the way to coma, the other on the way to sleep, which is very different.[25][26]

The affected person has a sensation of mental clouding described in the patient's own words as "foggy".[5] One patient said, "I thought it became like misty, in some way... the outlines were sort of fuzzy".[24] Others may describe a "spaced-out" feeling.[27] Affected people compare their overall experience to that of a dream, because, as in a dream, consciousness, attention, orientation to time and place, perception, and awareness are disturbed.[28] Barbara Schildkrout, a clinical instructor in psychiatry at the Harvard Medical School, described her subjective experience of clouding of consciousness, which she also called "mental fog", after taking a single dose of chlorpheniramine (an antihistamine for her allergy to cottonwood) on a cross-country road trip. She described feeling "out of it" and being in a "dreamy state". She described a sense of not trusting her own judgment and a dulled awareness, not knowing how much time had passed.[1] Clouding of consciousness is not the same thing as depersonalization, though people affected by both compare their experience to that of a dream. Psychometric tests produce little evidence of a relationship between clouding of consciousness and depersonalization.[29]

Brain fog may affect performance on virtually any cognitive task.[1] As one author put it, "It should be apparent that cognition is not possible without a reasonable degree of arousal."[3] Cognition includes perception, memory, learning, executive functions, language, constructive abilities, voluntary motor control, attention, and mental speed. Brain fog's most significant clinical features are inattention, thought process abnormalities, comprehension abnormalities, and language abnormalities.[14] The extent of the impairment is variable because inattention may impair several cognitive functions. Affected people may complain of forgetfulness, being "confused",[30] or being "unable to think straight".[30] Despite the similarities, subsyndromal delirium is not the same thing as mild cognitive impairment; the fundamental difference is that mild cognitive impairment is a dementia-like impairment, which does not involve a disturbance in arousal (wakefulness).[31]

Drug use and withdrawal

[edit]

Use of and withdrawal from certain recreational and prescription drugs has been shown to alter brain cognition and contribute to memory loss, impaired recall, emotional volatility, mood instability, and altered behavior.[32] It can also heighten stress, dysregulate pleasure and the basal ganglia's reward system, and limit executive control function by disrupting normal function of the prefrontal cortex, leading to difficulty concentrating, "organiz[ing] thoughts and activities, prioritiz[ing] tasks, manag[ing] time, and mak[ing] decisions".[33]

People may misuse substances as a means of self-medication for psychological/neuro-cognitive difficulties, masking symptoms during use periods but leading to a rebound or exacerbation of symptoms in the immediate post-abstinence period.[33][34] This may result from the users' dependency on and subsequent restriction from the substance in question, or from neurocognitive impairment / neurodegeneration resulting from use.[33]

Dopamine dysregulation

[edit]

As addictive behaviors persist, dopamine is depleted at a faster pace, and its receptors increasingly dulled by oversaturation, leading to a reduced sensitivity to dopamine produced naturally by the body over time.[35] It has been consistently shown that addicts present with both lower responsiveness to dopamine, particularly in D2 receptors, and lower dopamine production overall.[33][36][37] This, in turn, dysregulates the brain's natural reward mechanisms, leading to decreased motivation, anxiety, difficulty thinking and concentrating, impulsivity, fatigue, emotional blunting, short-term memory disruptions, forgetfulness, disorganization, loss of coordination and balance, and social withdrawal.[35][38]

This self-reinforcing process is often reversed with restriction from the substance in question. Initial acute impacts are pronounced, but dopamine levels begin to stabilize during the withdrawal period, albeit slowly, and eventually return to a healthy baseline.[35]

By substance

[edit]

Alcohol

[edit]
See also: Alcohol related brain damage

Heavy, progressive, and persistent alcohol abuse (alcohol use disorder (AUD)) lasting more than several years has been shown to lead to brain damage.[39] Cognitive difficulties related to alcohol use that do not progress into more severe illness are called alcohol-related brain damage (ARBD).[40] Symptoms include mild executive dysfunction as well as deficits in memory, coordination, motor control, and visuospatial skills.[40][41] Cognitive deficits differ significantly between patients, suggesting "that the functions affected by chronic alcohol consumption are dissociable and supported by different neural systems".[40]

Wernicke-Korsakoff Syndrome
[edit]
Main article: Wernicke–Korsakoff syndrome

Persistent alcohol use disorder lasting several years or more can contribute to severe malnutrition.[40] Alcohol abuse hinders the gut's ability to properly absorb critical nutrients, and the brain's ability to phosphorylate them.[40][42] Chief among these deficiencies is thiamine (Vitamin B-1). With an incidence rate as high as 12.5% in patients with alcoholism, such a deficiency can lead to Wernicke encephalopathy (WE), though this is reversible through rapid therapeutic treatment with thiamine and glucose.[40][42][43] This stage is characterized by confusion (of a more severe degree than brain fog), incoherence, motor impairments, loss of coordination and balance, and impairments in the visual domain.[43] The mortality rate for patients at this stage is around 20%. Roughly 12% of patients experience disease improvement, with chronic brain damage potentially being avoided with treatment, though not all cognitive effects are reversible.[42][43]

WE, if left untreated, can progress to Korsakoff syndrome (as is the case in roughly 68-80% of cases), an irreversible form of chronic amnesia. This stage is characterized by relief from severe confusion, less incoherence, and clear consciousness over the course of the day, but, in the longer term, severe anterograde memory impairments (both memory formation (anterograde amnesia) and recall), confabulation, hallucination, repetitive speech and action, severe executive dysfunction, lack of motivation, and emotional apathy.[40][42][43] Additionally, patients may experience symptoms more reminiscent of brain fog, including "deficits on tests of problem solving, working memory, cognitive flexibility, perseverative responding, and self-regulation."[40] Memory rehabilitation therapy may help to relieve symptoms; severe cases often require institutionalization.[43][44]

Cannabis

[edit]

The effects of cannabis on neurological function have become better known in recent years, with the overwhelming majority of research finding that cannabis impairs cognitive function. The duration and frequency of use and quantity and concentration of product consumed correlates with the degree and duration of impairment.[45][46][47] The immediate short-term effects of cannabis use can include "impaired short-term memory and motor coordination, altered judgment, paranoia, and psychosis".[48] Long-term use can lead to "altered brain development, poor educational outcomes, cognitive impairment, diminished quality of life", and increased risk of suicide.[48]

The rapid increase in the THC concentration of cannabis products in recent years has led to concern among physicians that it may contribute to adverse health effects among the general population, particularly adolescents and young adults.[46][47][49][50][51][52]

Cannabis use disorder
[edit]
Main article: Cannabis use disorder

A 40-year-long study in New Zealand followed roughly 1,000 people from age 3 to 45 to measure the impacts of cannabis usage on brain function and functional IQ. It found that long-term cannabis users (those who reported consistent or dependent usage of the drug at age 45 and at least one previous period of sustained heavy usage)[a] experienced a mean 5.5-point drop in IQ from childhood to adulthood.[45][53] These cognitive deficits "could not be explained by persistent tobacco, alcohol, or other illicit drug use, childhood socioeconomic status, low childhood self-control, or family history of substance dependence." Comparative groups fared significantly better; non-users of all substances were the only group to experience a positive change in IQ over the length of the study. Cannabis quitters (those with at least one previous instance of diagnosed cannabis dependency who reported no usage at the conclusion of the study) and recreational midlife users (those reporting use between 6 and 51 days per year in their 30s and 40s, with no history of weekly or dependent usage) experienced a smaller but nevertheless comparatively significant drop in IQ. Long-term users were the only group whose performance worsened on every cognitive benchmark assessment administered at the end of the study period.[53]

Presentation in psychotic disorders
[edit]

Numerous studies have shown that heavy cannabis users face a markedly higher risk of schizophrenia, bipolar disorder, and transient psychotic episodes than the general population, with up to 50% of those who experienced cannabis-induced psychosis going on to develop schizophrenia.[34][54][55] But a 2010 meta-analysis of previous research in the Schizophrenia Bulletin showed evidence that those same people have a paradoxically lower risk of neurocognitive difficulties; use of the substance substantially increased the prevalence of positive symptoms, but was simultaneously associated with reduced neurocognitive deficits or, in some cases, boosted cognitive performance (e.g., visual memory, working memory, and executive function).[54][56]

Heart health and cerebrovascular deficits
[edit]

Studies published over the past decade have shown that cannabis use (particularly in cases of heavy use or dosage) is associated with significantly increased risk of cardiovascular deficits and/or coronary events in people under age 50, particularly ischemic strokes and myocardial infarctions (heart attacks).[57][58][59] This effect is especially pronounced in young children.[60][61] Despite having an immediate short-term impact of lowering blood pressure, cannabis has been associated with hypertension in regular and heavy users.[52] This, in turn, can restrict the flow of oxygen to the brain, leading to "forgetfulness, trouble with learning, memory and comprehension".[62] Continued restriction can lead to cerebral small and large vessel disease later in life, which significantly increases the likelihood of dementia onset.[63]

Disease and health complications

[edit]

Anxiety / general anxiety disorder (GAD)

[edit]
Main articles: Anxiety, General anxiety disorder, and Anxiety disorder

Anaemia

[edit]
Main article: Anaemia

Attention deficit hyperactivity disorder (ADHD)

[edit]
Main article: Attention deficit hyperactivity disorder

Brain fog has been shown to be a primary symptom of ADHD, though it can also be due to associated co-morbidities. In adults, ADHD typically presents as difficulties with memory and attention, as opposed to the hyperactivity typically observed in children.[64]

Autism

[edit]
Main articles: Autism and Autistic burnout

Cancer and chemotherapy

[edit]
See also: Chemotherapy and Post-chemotherapy cognitive impairment

Patients undergoing chemotherapy often present with brain fog (often called "chemo brain", "chemo fog", or chemotherapy-induced cognitive impairment (CICI)), a complication of the all-encompassing damage done to the brain and body over the course of treatment.[65] Patients often report experiencing fatigue and difficulty with memory, language use, visuo-spatial skills, immediate and delayed recall, processing speed, and executive function.[66][67] Such difficulties can surface both during and after treatment, with cognitive deficits being reported as much as 21 years after treatment.[66] But some studies have found that neuro-cognitive deficits were present in some patients before beginning treatment.[66] Hypotheses for the cause of these symptoms include "direct neurotoxicity, [blood–brain barrier] disruption, decreased hippocampal neurogenesis, white matter abnormalities, secondary neuro-inflammatory response and increased oxidative stress".[67]

Symptoms can be exacerbated by additional side effects of treatment, including sleep cycle impairment, dietary issues, fatigue, and imbalanced mood.[68] Though therapeutic treatments are not yet widely available, common recommendations for accelerating neuro-regeneration include regular physical exercise, proper sleep and nutrition, stress reduction, and engagement in pleasurable activity.[68]

Criticism and counterarguments

[edit]

Research published in 2017 in Neuroscience & Biobehavioral Reviews criticized the results of earlier meta-analyses and studies for their inconsistent assessment and control methods and for being broadly cross-sectional: there was no real means by which age, cancer severity, or prior treatment could be accounted for in determining the degree to which the effects of chemotherapy on cognitive function were real. That same meta-analysis found no significant difference in magnitude between the reported neurocognitive impairment of cancer survivors who underwent chemotherapy and those who did not.[66] Additionally, little difference was shown between the moderating effect of time on cognitive impairment between those two groups, though statistical complications that may have affected such determination were acknowledged.[66]

Chronic fatigue

[edit]
Main article: Myalgic encephalomyelitis/chronic fatigue syndrome

In chronic fatigue syndrome (CFS), also known as myalgic encephalomyelitis, the CDC's recommended criteria for diagnosis[69] include that one of the following symptoms must be present:[69]

  • Problems with thinking and memory (cognitive dysfunction, sometimes described as "brain fog")
  • While standing or sitting upright, lightheadedness, dizziness, weakness, fainting, or vision changes may occur (orthostatic intolerance)

Patients diagnosed with CFS have been shown to experience reduced activation of the basal ganglia, responsible for the brain's reward system, and a primary center for inflammation therein. Treatment thus centers upon increasing dopaminergic activity/receptivity in the brain and/or preventing inflammation.[65]

Chronic pain

[edit]

Brain fog is a common symptom in many illnesses where chronic pain is a major component.[4] Brain fog affects 15% to 40% of those with chronic pain as their major illness.[70] In such illnesses, pain processing may use up resources, decreasing the brain's ability to think effectively.[4]

Chronic sleep deprivation

[edit]
Main article: Chronic sleep deprivation

Chronic stress

[edit]
Main article: Chronic stress

Chronic traumatic encephalopothy

[edit]
Main article: Chronic traumatic encephalopathy

Cognitive disengagement syndrome

[edit]

Cognitive disengagement syndrome was implicated in the expression of brain fog symptoms.[71]

COVID-19

[edit]
See also: COVID-19

Patients recovering from COVID-19 have reported experiencing brain fog, which can reflect a wide variety of neurological and psychological symptoms linked to COVID-19.[72][73] Symptoms can persist for months, even years, and are often characterized by fatigue, difficulties with "attention...memory recall, language and executive functioning", as well as depression and anxiety.[74][75][76] Descriptions are necessarily subjective, with some patients describing cognitive symptoms as "muddled or fuzzy thoughts", like "a bad wi-fi connection to a router", being "in slow motion", or "disappear[ing] like 'smoke' or a 'dream'".[65]

COVID has also been shown to cause encephalopathy, though this is more common in elderly patients and those with preexisting chronic conditions.[77] The Alpha and Delta variants of the virus were characterized by severe cognitive impairment at the time of infection, followed by slow recovery.[74]

A 2025 Rutgers Health study highlighted the need for greater attention to long COVID symptoms in young children, given their necessarily lesser ability to accurately report and explain their symptoms. Infants and toddlers diagnosed with long COVID were found to experience greater "difficulty sleeping, fussiness, and poor appetite", alongside other physical symptoms, while preschoolers were more likely to experience "daytime tiredness and low energy".[78]

Causes and treatment

[edit]

Research from the UK Biobank in 2022 showed comparative signs of neurodegeneration and cognitive decline amongst a group of 401 middle-aged and elderly COVID-19 patients (importantly, excluding 15 patients who had been hospitalized with the illness over that period) over roughly five months. The study focused mainly on imaging of the limbic system, with evidence that the disruption of the olfactory system played a critical role in the disease's neurodegenerative effects. The researchers found that, in comparison with a control, there were decreases in total brain size, evidence of cognitive decline, "reduction[s] in grey matter thickness and tissue contrast in the orbitofrontal cortex and parahippocampal gyrus", and markers of tissue damage in regions of the brain connected to the primary olfactory cortex.[79] Over the observation period, those who had tested positive for COVID-19 lost 0.2% to 2% more brain matter than those who had not contracted the illness, the latter equivalent to 10 years worth of normal age-based degeneration.[77][80][81] COVID-19 patients also showed disrupted contact between different regions of the brain.[77]

People with long COVID are significantly more likely to experience gastrointestinal dysfunction and have "reported worse anxiety, depression, and quality of life".[82] COVID is thought to reduce the natural production of serotonin in the gut, which can disrupt normal cognitive processes and cause symptoms of brain fog.[83] Studies of mice "[bio]-engineered to mimic long COVID in humans" showed that cognitive difficulties could be relieved through treatment with Prozac.[84]

Initially, it was thought that the presentation of brain fog in long COVID shared molecular features with Alzheimer's disease.[85] This was disproved in 2024 by researchers from Rutgers University. 68% of COVID-19 patients who participated in their study had reported "a decline in thinking or memory", but comparison of cognitive testing scores between patients found similarities between the reported experiences of those with proven cognitive impairment and those whose experience was deemed subjective (i.e greater "fatigue, sleepiness, depression, and anxiety" than long COVID patients who reported no persistent neuro-intellectual symptoms), leading to uncertainty over the effects of long COVID on cognitive performance.[86] Over two years, only half of patients involved in the study reported improvements in persistent cognitive difficulties.[87][88] It was found that the persistence of symptoms was linked to auto-immune markers of viral infection, with the neurological changes associated with Alzheimer's not found in long COVID patients.[87][86] Researchers believe that interferons, markers of a strong autoimmune response to infection, were a key aspect of symptom relief, with those whose autoimmune response was lacking showing few signs of improvement.[88] Interferon-based therapies and antiviral drugs shown to be successful against the virus were found to be the best way to alleviate symptoms.[87]

A 2025 study published in Nature found evidence that the SARS-CoV-2 virus was neuroinvasive, and could linger in the brain stem through slow replication regardless of the prevalence of infection in the body. Viral RNA and replicative virus were discovered in the brainstems of golden hamsters 80 days after initial infection. Subjects displayed signs of neurodegeneration, and "altered expression of genes involved in the dopaminergic and glutamatergic synapses, in energy metabolism, and in proteostasis."[76]

Depression

[edit]
Main articles: Biology of depression and Major depressive disorder

Encephalitis

[edit]
Main article: Encephalitis

Fibromyalgia

[edit]

Many people with fibromyalgia experience cognitive problems[89] (often called "fibrofog"), which may involve impaired concentration,[90][91][unreliable medical source?][92] problems with short-[93] and long-term memory, short-term memory consolidation,[93] working memory,[94] impaired speed of performance,[93] inability to multitask, cognitive overload,[93] and diminished attention span. About 75% of fibromyalgia patients report significant problems with concentration, memory, and multitasking.[95] A 2018 meta-analysis found that the largest differences between fibromyalgia patients and healthy subjects were in inhibitory control, memory, and processing speed.[95] Many of these are also common symptoms of ADHD, and studies have linked the two conditions, to the point that a fibromyalgia diagnosis has been proposed as an indication to screen for ADHD.[96][97][98] It is alternatively hypothesized that increased pain compromises attention systems, resulting in cognitive problems.[95]

Gut health

[edit]
Main article: Gut–brain axis

The human digestive system is lined with more than 100 million nerve cells, referred to as the enteric nervous system (ENS), which is primarily responsible for regulating gastrointestinal activity.[99] The system is connected to the central nervous system by means of the gut-brain axis, a neurotransmission channel anchored by the vagus nerve.[84] This system and the gut microbiome play a critical role in influencing cognitive function and controlling inflammatory response.[100][101] More than 90% of the body's serotonin (which assists with memory and helps maintain calm and focus in the brain) is produced in the gut, alongside other key neurotransmitters, molecules implicated in interoception, and fatty acids; much of this takes place by means or with the help of immune cells in and microbiota of the gut.[84][102][100][103][cleanup needed]

Dysregulation in either system can affect the other. Gut irritation can trigger stress and cognitive difficulties as well as changes in mood or behavior in the brain.[102] Myriad cognitive and emotional challenges can, in turn, produce irritation in the gut, creating a positive feedback loop that can provoke further instability in both systems.[102] "Psychosocial factors influence the actual physiology of the gut, as well as symptoms".[104] People with irritable bowel syndrome (IBS) and other functional gastrointestinal disorders are known to experience psychiatric illness, depression, anxiety, anaemia, and fatigue at a higher rate than the general public.[99][102][105][106] High stress and anxiety, depression, and psychiatric disorders have also shown to produce higher-than-average rates of gastrointestinal disease, such as IBS, constipation, and diarrhea, and to influence the makeup of the gut microbiota, which can in turn heighten stress and worsen depression.[105][107][108] Fecal transplants from humans with depression to rats have shown that depressive and anxiogenic symptoms may be directly influenced by the makeup of the gut microbiome.[84][109]

Prescriptions

[edit]

Certain antidepressant regimens and/or cognitive behavioral therapy (CBT) have been shown to relieve symptoms of functional gastrointestinal disorders in some patients, which is believed to be a result of their calming effect on the ENS.[99] The vast majority of sources encourage improvement in one's diet as a means of promoting a healthy gut microbiome, recommending that they be plant-rich and fiber intensive.[110] This includes the proper provisioning of prebiotics (proposed as a prerequisite to the proper development of an effective microbiome in the long term), reasonably significant quantities of soluble and insoluble fiber, probiotics (fermented foods), anti-oxidants, and anti-inflammatories.[84][102][103][106] The controlled and limited use of antibiotics may be prescribed by doctors to clear persistent bacterial infection in the gastrointestinal tract.[110][111]

Hypersomnia

[edit]
Main articles: Hypersomnia and Idiopathic hypersomnia

Hypoglycemia and diabetes

[edit]
Main article: Hypoglycemia

Hypothyroidism

[edit]

Brain fog and additional neuro-cognitive difficulties are a common symptom of hypothyroidism.[112][113][114] Symptoms often include "fatigue, depressed mood, and cognitive difficulties, including problems with memory and word-finding".[115] In some cases, this may result from insufficient treatment of thyroid deficiencies, or additional, untreated co-morbidities, such as "depression, sleep apnea, or vitamin B12 deficiency".[113] A 2022 survey showed that 79.2% of those with the condition reported experiencing brain fog to some extent, selecting the options "frequently" or "all the time".[113] One American Thyroid Association study found that among a cohort of 5,000 patients presenting with hypothyroidism, more than 95% of those experiencing brain fog (a majority of study participants) reported experiencing "fatigue, forgetfulness, sleepiness and difficulty focusing".

It is unclear how hypothyroidism leads to brain fog, but levothyroxine has been shown to reduce cognitive impairment in some patients.[116] However, roughly 10-15% of those receiving such treatment experience persistent cognitive deficits and reduced quality of life, with some believing this demonstrates persistent hypothyroidism at the cellular level despite tests showing TSH results in the normal range.[117] This may lead patients to seek higher dosage, which doctors often dismiss, or alternative therapies, such as desiccated thyroid extract (DTE), despite the lack of evidence supporting its use.[115][117] Some patients, more commonly those over age 50, reported improvement with the addition of liothyronine (L-T3) to their treatment regimen, though some researchers question its efficacy .[114][115] Rest and exercise have also been shown to help alleviate symptoms.[113][114]

Lupus

[edit]
Main article: Lupus

Lyme disease

[edit]

Lyme disease's neurologic syndrome, called Lyme encephalopathy, is associated with subtle memory and cognitive difficulties, among other issues.[118] Lyme can cause a chronic encephalomyelitis that resembles multiple sclerosis. It may be progressive and can involve cognitive impairment, migraines, balance problems, and other symptoms.[citation needed]

Menopause

[edit]
Main article: Menopause

Menopause, officially described as the end of menstruation and reproductive hormone production in those assigned female at birth who still possess primary female sexual characteristics, can be characterized in all stages by deficits in cognitive performance (sometimes referred to as "meno-fog").[119][120][121][122] Though symptoms vary significantly between patients depending on factors such as genetics, ethnicity, and preexisting conditions, brain fog has been shown to be exceptionally common, with up to 80% of people experiencing it at some point over the course of transition.[119][122][123] Cognitive dysfunction is most prevalent in the perimenopausal period, particularly in the domains of informational acquisition, concentration, and memory; anecdotal evidence suggests that absent-mindedness and confusion are common in several stages. But these symptoms are often temporary, and begin to relieve as the postmenopausal period progresses.[119][121][122][124]

A 2022 study published in Menopause analyzed a group of 404 women from rural India between the ages of 40 and 65, assessing the severity of their menopausal symptoms (on the Greene Climacteric Scale) and cognitive performance (scoring orientation, registration, attention, recall, and language and visuospatial skills by means of the Hindi Mini-Mental State Examination).[123][125] Women with severe menopausal symptoms presented with significantly lower mean performance across all cognitive domains.[125] The study additionally found evidence that common menopause symptoms, particularly severe depression and greater sexual dysfunction, were closely linked to cognitive difficulties, though it failed to establish a causal relationship between them, meaning there was little indication whether one preceded the other.[121][123][125] Symptoms of "depression, total psychological, sexual, and somatic dysfunction" were most severe for late postmenopausal women (those whose periods had ceased more than 5 years before the time of the study); anxiety and hot flashes were found to be most common among those in early postmenopause (whose periods had ceased less than 5 years earlier).[121][126] The study found no relationship between the severity of vasomotor symptoms (hot flashes) and cognitive performance.[123]

Cognitive deficits are believed to result in part from the sudden drop in estrogen across "virtually every organ", contributing in turn to hormonal imbalances that disrupt the brain's and body's natural processes.[121][124] It is believed that estrogen plays a crucial role for people of all genders in the function of the prefrontal cortex, the proper functioning of which is critical to executive processes such as "inhibiting distracting information and stimuli, planning, evaluating consequences when making decisions, and working memory."[124] The transition affects serotonergic and dopaminergic expression, contributing to imbalances in cognition and mood.[122] Additionally, elevated stress and a subsequent increase in cortisol may contribute to memory and processing difficulties.[122][127]

Prescriptions depend upon determination of the cause of cognitive dysfunction. Reducing stress, challenging oneself intellectually, maintaining proper fitness and nutrition, adequate hydration, sleep (known to be particularly dysfunctional amid menopause), sun exposure, and social support are generally known to assist in improving cognition.[119][121][122] Hormone replacement therapy is thought to help relieve cognitive and broader symptoms in some patients.[122]

Menstruation

[edit]
Main articles: Premenstrual syndrome, Menstruation cycle, and Menstruation

Migraine disorders

[edit]
Main article: Migraine

Mold exposure

[edit]

Brain fog and other neurological symptoms may also result from mold exposure.[128][129][130][131][132] This may be due to mycotoxin exposure and consequent innate immune system activation and inflammation, including in the central nervous system.[133][128][129][130][131][132] But adverse neurological health effects of mold exposure are controversial due to inadequate research and data, and more research is needed in this area.[133][134][135][128][130][132]

Obsessive-compulsive disorder (OCD)

[edit]
Main article: Obsessive–compulsive disorder

Oophorectomy and ovariectomy (OVX)

[edit]
Main articles: Oophorectomy and Ovariectomy

Pregnancy

[edit]
Main articles: Prenatal stress, Postpartum depression, and Postpartum period

Psychotic disorders

[edit]
Main articles: Schizophrenia, Schizoaffective disorder, Bipolar disorder, Postpartum psychosis, and Psychosis

See also

[edit]

Notes

[edit]
  1. ^ Weekly or more (as reported at ages 18, 21, 26, 32, 38, and 45)[45][53]

References

[edit]
  1. ^ a b c Schildkrout, Barbara (2011). Unmasking Psychological Symptoms. John Wiley & Sons. pp. 183–184. ISBN 978-0-470-63907-8.
  2. ^ Basavanna, M. (2000). Dictionary of Psychology. Allied Publishers. p. 65. ISBN 81-7764-030-5.
  3. ^ a b c d e Plum and Posner's diagnosis of stupor and coma. Oxford University Press. 2007. pp. 5–6. ISBN 978-0-19-988653-1.
  4. ^ a b c Dass, Ronessa; Kalia, Mohini; Harris, Jocelyn; Packham, Tara (2023-12-31). "Understanding the Experience and Impacts of Brain Fog in Chronic Pain: A Scoping Review". Canadian Journal of Pain. 7 (1) 2217865. doi:10.1080/24740527.2023.2217865. ISSN 2474-0527. PMC 10334862. PMID 37441085.
  5. ^ a b Augusto Caraceni; Luigi Grassi (2011). Delirium: Acute Confusional States in Palliative Medicine. Oxford University Press. p. 82. ISBN 978-0-19-957205-2.
  6. ^ a b c d Anastasian, Zirka H.; Ornstein, Eugene; Heyer, Eric J. (2009-09-01). "Delayed Arousal". Anesthesiology Clinics. Problems with Geriatric Anesthesia Patients. 27 (3): 429–450. doi:10.1016/j.anclin.2009.07.007. ISSN 1932-2275. PMC 3036001. PMID 19825485.
  7. ^ Georg Friedrich Christoph Greiner (1817). Der Traum und das fieberhafte Irreseyn: ein physiologisch-psychologischer Versuch. F. A Brockhaus. OCLC 695736431.
  8. ^ Augusto Caraceni; Luigi Grassi (2011). Delirium: Acute Confusional States in Palliative Medicine. Oxford University Press. p. 2. ISBN 978-0-19-957205-2.
  9. ^ George Stein; Greg Wilkinson (2007). Seminars in General Adult Psychiatry. RCPsych Publications. p. 490. ISBN 978-1-904671-44-2.
  10. ^ Dan G. Blazer; Adrienne O. van Nieuwenhuizen (2012). "Evidence for the Diagnostic Criteria of Delirium". Curr Opin Psychiatry. 25 (3): 239–243. doi:10.1097/yco.0b013e3283523ce8. PMID 22449764. S2CID 39516431.
  11. ^ Anthony David; Simon Fleminger; Michael Kopelman; Simon Lovestone; John Mellers (April 2012). Lishman's Organic Psychiatry: A Textbook of Neuropsychiatry. John Wiley & Sons. p. 5. ISBN 978-0-470-67507-6.
  12. ^ Fang Gao Smith (2010). Core Topics in Critical Care Medicine. Cambridge University Press. p. 312. ISBN 978-1-139-48968-3.
  13. ^ a b c Sébastien Ouimet; Riker, R; Bergeron, N; Cossette, M; Kavanagh, B; Skrobik, Y; et al. (2007). "Subsyndromal delirium in the ICU: evidence for a disease spectrum". Intensive Care Med. 33 (6): 1007–1013. doi:10.1007/s00134-007-0618-y. PMID 17404704. S2CID 20565946.
  14. ^ a b c d David Meagher; Adamis, D.; Trzepacz, P.; Leonard, M.; et al. (2012). "Features of subsyndromal and persistent delirium". The British Journal of Psychiatry. 200 (1): 37–44. doi:10.1192/bjp.bp.111.095273. PMID 22075650.
  15. ^ Augusto Caraceni; Luigi Grassi (2011). Delirium: Acute Confusional States in Palliative Medicine. Oxford University Press. p. 11. ISBN 978-0-19-957205-2.
  16. ^ Friedman, Garrett (12 June 2023). "The Current of Consciousness: Neural Correlates and Clinical Aspects" (PDF). Current Neurology and Neuroscience Reports. 23. doi:10.1007/s11910-023-01276-0. Retrieved 6 Dec 2025.
  17. ^ Frith, Chris. "The role of the prefrontal cortex in higher cognitive functions". Cognitive Brain Research. 5: 180. doi:10.1016/S0926-6410(96)00054-7.
  18. ^ Tindall, Suzie C. (1990), Walker, H. Kenneth; Hall, W. Dallas; Hurst, J. Willis (eds.), "Level of Consciousness", Clinical Methods: The History, Physical, and Laboratory Examinations (3rd ed.), Boston: Butterworths, ISBN 978-0-409-90077-4, PMID 21250221, retrieved 2025-11-25
  19. ^ a b c Saper, Clifford B.; Scammell, Thomas E.; Lu, Jun (2005-10-26). "Hypothalamic regulation of sleep and circadian rhythms". Nature. 437 (7063): 1257–1263. Bibcode:2005Natur.437.1257S. doi:10.1038/nature04284. ISSN 1476-4687. PMID 16251950.
  20. ^ a b Augusto Caraceni; Luigi Grassi (2011). Delirium: Acute Confusional States in Palliative Medicine. Oxford University Press. pp. 19–21. ISBN 978-0-19-957205-2.
  21. ^ Yudofsky & Hales (2008). The American Psychiatric Publishing textbook of neuropsychiatry and behavioral neurosciences. American Psychiatric Pub. p. 477. ISBN 978-1-58562-239-9.
  22. ^ Roger A. MacKinnon; Robert Michels; Peter J. Buckley (2006). The Psychiatric Interview in Clinical Practice (2nd ed.). American Psychiatric Publishing, Inc. pp. 462–464.
  23. ^ Plum and Posner's diagnosis of stupor and coma. Oxford University Press. 2007. p. 8. ISBN 978-0-19-804336-2.
  24. ^ a b G Sorensen Duppils; K Wikblad (May 2007). "Patients' experiences of being delirious". Journal of Clinical Nursing. 16 (5): 810–818. doi:10.1111/j.1365-2702.2006.01806.x. PMID 17462032.
  25. ^ Lipowski ZJ. (1967). "Delirium, clouding of consciousness and confusion". Journal of Nervous and Mental Disease. 145 (3): 227–255. doi:10.1097/00005053-196709000-00006. PMID 4863989.
  26. ^ William Alwyn Lishman (1998). Organic Psychiatry: The Psychological Consequences of Cerebral Disorder. John Wiley & Sons. p. 4.
  27. ^ Fred Ovsiew, M.D. (1999). Neuropsychiatry and Mental Health Services. American Psychiatric Press, Inc. p. 170. ISBN 0-88048-730-5.
  28. ^ Simon Fleminger (2002). "Remembering delirium". The British Journal of Psychiatry. 180 (1): 4–5. doi:10.1192/bjp.180.1.4. PMID 11772842.
  29. ^ Sedman, G. (July 1970). "Theories of Depersonalization: A Re-appraisal". British Journal of Psychiatry. 117 (536): 1–14. doi:10.1192/s0007125000192104. PMID 4920886. S2CID 246610704.
  30. ^ a b John Noble; Harry L. Greene (1996). Textbook of Primary Care Medicine. Mosby. p. 1325.
  31. ^ Plum and Posner's diagnosis of stupor and coma. Oxford University Press. 2007. p. 7. ISBN 978-0-19-988653-1.
  32. ^ "Brain recovery after alcohol and other drug use - Alcohol and Drug Foundation". adf.org.au. Retrieved 2025-09-28.
  33. ^ a b c d Administration (US), Substance Abuse and Mental Health Services; General (US), Office of the Surgeon (November 2016), "THE NEUROBIOLOGY OF SUBSTANCE USE, MISUSE, AND ADDICTION", Facing Addiction in America: The Surgeon General's Report on Alcohol, Drugs, and Health [Internet], US Department of Health and Human Services, retrieved 2025-11-19
  34. ^ a b Starzer, Marie Stefanie Kejser; Nordentoft, Merete; Hjorthøj, Carsten (April 2018). "Rates and Predictors of Conversion to Schizophrenia or Bipolar Disorder Following Substance-Induced Psychosis". American Journal of Psychiatry. 175 (4): 343–350. doi:10.1176/appi.ajp.2017.17020223. ISSN 0002-953X. PMID 29179576.
  35. ^ a b c "Dopamine: Function, Relation With Addiction, Dysregulation Effect, And Recovery". White Light Behavioral Health. 2024-11-17. Retrieved 2025-11-19.
  36. ^ Volkow, N. D.; Wang, G.-J.; Fowler, J. S.; Logan, J.; Gatley, S. J.; Hitzemann, R.; Chen, A. D.; Dewey, S. L.; Pappas, N. (1997-04-24). "Decreased striatal dopaminergic responsiveness in detoxified cocaine-dependent subjects". Nature. 386 (6627): 830–833. Bibcode:1997Natur.386..830V. doi:10.1038/386830a0. ISSN 1476-4687. PMID 9126741.
  37. ^ Volkow, N. D.; Tomasi, D.; Wang, G.-J.; Logan, J.; Alexoff, D. L.; Jayne, M.; Fowler, J. S.; Wong, C.; Yin, P.; Du, C. (2014-06-10). "Stimulant-induced dopamine increases are markedly blunted in active cocaine abusers". Molecular Psychiatry. 19 (9): 1037–1043. doi:10.1038/mp.2014.58. ISSN 1476-5578. PMC 4827430. PMID 24912491.
  38. ^ "Dopamine Deficiency: Symptoms, Causes & Treatment". Cleveland Clinic. Archived from the original on 2025-08-19. Retrieved 2025-11-19.
  39. ^ "Alcohol-related brain damage (ARBD): what is it and who gets it? | Alzheimer's Society". www.alzheimers.org.uk. Retrieved 2025-11-26.
  40. ^ a b c d e f g h Zahr, Natalie M.; Kaufman, Kimberley L.; Harper, Clive G. (2011-04-12). "Clinical and pathological features of alcohol-related brain damage". Nature Reviews. Neurology. 7 (5): 284–294. doi:10.1038/nrneurol.2011.42. ISSN 1759-4766. PMC 8121189. PMID 21487421.
  41. ^ van Holst, Ruth Janke; Schilt, Thelma (March 2011). "Drug-related decrease in neuropsychological functions of abstinent drug users". Current Drug Abuse Reviews. 4 (1): 42–56. doi:10.2174/1874473711104010042. ISSN 1874-4745. PMID 21466500.
  42. ^ a b c d Oudman, Erik; Van der Stigchel, Stefan; Postma, Albert; Wijnia, Jan W.; Nijboer, Tanja C. W. (2014-05-27). "A Case of Chronic Wernicke's Encephalopathy: A Neuropsychological Study". Frontiers in Psychiatry. 5: 59. doi:10.3389/fpsyt.2014.00059. ISSN 1664-0640. PMC 4034510. PMID 24904442.
  43. ^ a b c d e "Wernicke-Korsakoff Syndrome | National Institute on Alcohol Abuse and Alcoholism (NIAAA)". www.niaaa.nih.gov. Retrieved 2025-11-26.
  44. ^ THOMSON, ALLAN D.; MARSHALL, E. JANE (2005-12-29). "The Natural History and Pathophysiology of Wernicke's Encephalopathy and Korsakoff's Psychosis". Alcohol and Alcoholism. 41 (2): 151–158. doi:10.1093/alcalc/agh249. ISSN 1464-3502. PMID 16384871. Archived from the original on 2023-03-20.
  45. ^ a b c Hill, Kevin; Hsu, Michael (2022-06-14). "Cognitive effects in midlife of long-term cannabis use". Harvard Health. Retrieved 2025-09-29.
  46. ^ a b Bourque, Josiane; Potvin, Stéphane (2021-06-10). "Cannabis and Cognitive Functioning: From Acute to Residual Effects, From Randomized Controlled Trials to Prospective Designs". Frontiers in Psychiatry. 12 596601. doi:10.3389/fpsyt.2021.596601. ISSN 1664-0640. PMC 8222623. PMID 34177633.
  47. ^ a b "THC Content in Cannabis Has Surged: Here's What You Need to Know". Boston University. 2025-05-12. Retrieved 2025-09-29.
  48. ^ a b Bahji, Anees; Stephenson, Callum; Tyo, Richard; Hawken, Emily R.; Seitz, Dallas (2020-04-09). "Prevalence of Cannabis Withdrawal Symptoms Among People With Regular or Dependent Use of Cannabinoids: A Systematic Review and Meta-analysis". JAMA Network Open. 3 (4): e202370. doi:10.1001/jamanetworkopen.2020.2370. PMC 7146100. PMID 32271390.
  49. ^ Mallenbaum, Carly (2025-04-18). "THC in pot is way more potent than it was decades ago". Axios. Retrieved 2025-09-29.
  50. ^ ElSohly, Mahmoud A.; Chandra, Suman; Radwan, Mohammed; Majumdar, Chandrani Gon; Church, James C. (June 2021). "A Comprehensive Review of Cannabis Potency in the United States in the Last Decade". Biological Psychiatry. Cognitive Neuroscience and Neuroimaging. 6 (6): 603–606. doi:10.1016/j.bpsc.2020.12.016. ISSN 2451-9030. PMID 33508497.
  51. ^ Li, Ruixuan; Tao, Feng (2025). "Effects of Cannabis Exposure on Adolescent Health and Development: A Narrative Review". Current Drug Research Reviews. 17 (2): 160–169. doi:10.2174/0125899775273727231224185028. PMC 12376134. PMID 40761110.
  52. ^ a b Testai, Fernando D.; Gorelick, Philip B.; Aparicio, Hugo J.; Filbey, Francesca M.; Gonzalez, Raul; Gottesman, Rebecca F.; Melis, Miriam; Piano, Mariann R.; Rubino, Tiziana; Song, Sarah Y. (2022-02-10). "Use of Marijuana: Effect on Brain Health: A Scientific Statement From the American Heart Association". Stroke. 53 (4). On behalf of the American Heart Association Stroke Brain Health Science Subcommittee of the Stroke Council; Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Cardiovascular and Stroke Nursing; Council on Lifestyle and Cardiometabolic Health; and Council on Peripheral Vascular Disease: e176 – e187. doi:10.1161/STR.0000000000000396. PMID 35142225.
  53. ^ a b c Meier, Madeline H.; Caspi, Avshalom; Knodt, Annchen R.; Hall, Wayne; Ambler, Antony; Harrington, HonaLee; Hogan, Sean; M. Houts, Renate; Poulton, Richie; Ramrakha, Sandhya; Hariri, Ahmad R.; Moffitt, Terrie E. (2022-03-08). "Long-Term Cannabis Use and Cognitive Reserves and Hippocampal Volume in Midlife". American Journal of Psychiatry. 179 (5): 362–374. doi:10.1176/appi.ajp.2021.21060664. ISSN 0002-953X. PMC 9426660. PMID 35255711.
  54. ^ a b Seddon, Jennifer L.; Birchwood, Max; Copello, Alex; Everard, Linda; Jones, Peter B.; Fowler, David; Amos, Tim; Freemantle, Nick; Sharma, Vimal; Marshall, Max; Singh, Swaran P. (May 2016). "Cannabis Use Is Associated With Increased Psychotic Symptoms and Poorer Psychosocial Functioning in First-Episode Psychosis: A Report From the UK National EDEN Study". Schizophrenia Bulletin. 42 (3): 619–625. doi:10.1093/schbul/sbv154. ISSN 1745-1701. PMC 4838086. PMID 26536902.
  55. ^ Rognli, Eline B.; Heiberg, Ina H.; Jacobsen, Bjarne K.; Høye, Anne; Bramness, Jørgen G. (2023-05-03). "Transition From Substance-Induced Psychosis to Schizophrenia Spectrum Disorder or Bipolar Disorder". American Journal of Psychiatry. 180 (6): 437–444. doi:10.1176/appi.ajp.22010076. hdl:10037/32997. ISSN 0002-953X. PMID 37132221.
  56. ^ Yücel, Murat; Bora, Emre; Lubman, Dan I.; Solowij, Nadia; Brewer, Warrick J.; Cotton, Sue M.; Conus, Philippe; Takagi, Michael J.; Fornito, Alex; Wood, Stephen J.; McGorry, Patrick D.; Pantelis, Christos (March 2012). "The impact of cannabis use on cognitive functioning in patients with schizophrenia: a meta-analysis of existing findings and new data in a first-episode sample". Schizophrenia Bulletin. 38 (2): 316–330. doi:10.1093/schbul/sbq079. ISSN 1745-1701. PMC 3283159. PMID 20660494.
  57. ^ Jouanjus, Emilie; Raymond, Valentin; Lapeyre-Mestre, Maryse; Wolff, Valérie (2017-04-21). "What is the Current Knowledge About the Cardiovascular Risk for Users of Cannabis-Based Products? A Systematic Review". Current Atherosclerosis Reports. 19 (6): 26. doi:10.1007/s11883-017-0663-0. ISSN 1534-6242. PMID 28432636.
  58. ^ Kamel, Ibrahim; Mahmoud, Ahmed K.; Twayana, Anu Radha; Younes, Ahmed M.; Horn, Benjamin; Dietzius, Harold (May 2025). "Myocardial Infarction and Cardiovascular Risks Associated With Cannabis Use". JACC: Advances. 4 (5) 101698. doi:10.1016/j.jacadv.2025.101698. PMC 12235408. PMID 40104933.
  59. ^ "Cannabis Use Substantially Increases Risk of Heart Attack". American College of Cardiology. Retrieved 2025-09-28.
  60. ^ Lehman, Charles (2024-07-03). "The Real Problem With Legal Weed". New York Times Magazine. Retrieved 2025-09-28.
  61. ^ Tweet, Marit; Nemanich, Antonia; Wahl, Michael (2023-02-01). "Pediatric Edible Cannabis Exposures and Acute Toxicity: 2017–2021". Pediatrics. 151 (2) e2022057761. doi:10.1542/peds.2022-057761. ISSN 0031-4005. PMID 36594224. Archived from the original on 2025-08-06.
  62. ^ Mittal, Sanjay. "6 Signs and Symptoms of Hypertension (High BP) | Medanta". Medanta. Retrieved 2025-09-29.
  63. ^ Gąsecki, Dariusz; Kwarciany, Mariusz; Nyka, Walenty; Narkiewicz, Krzysztof (2013-10-23). "Hypertension, brain damage and cognitive decline". Current Hypertension Reports. 15 (6): 547–558. doi:10.1007/s11906-013-0398-4. ISSN 1534-3111. PMC 3838597. PMID 24146223.
  64. ^ "Is that brain fog really adult ADHD?". Harvard Health. 2018-11-01. Retrieved 2025-11-23.
  65. ^ a b c Loftus, Mary (Summer 2023). "Lost in a Brain Fog". news.emory.edu. Retrieved 2025-11-19.
  66. ^ a b c d e Bernstein, Lori J.; McCreath, Graham A.; Komeylian, Zahra; Rich, Jill B. (2017-12-01). "Cognitive impairment in breast cancer survivors treated with chemotherapy depends on control group type and cognitive domains assessed: A multilevel meta-analysis". Neuroscience & Biobehavioral Reviews. 83: 417–428. doi:10.1016/j.neubiorev.2017.10.028. ISSN 0149-7634. PMID 29092778.
  67. ^ a b Mounier, Noha M.; Abdel-Maged, Amany El-Shahawy; Wahdan, Sara A.; Gad, Amany M.; Azab, Samar S. (2020-10-01). "Chemotherapy-induced cognitive impairment (CICI): An overview of etiology and pathogenesis". Life Sciences. 258 118071. doi:10.1016/j.lfs.2020.118071. ISSN 0024-3205. PMID 32673664 – via Elsevier Science Direct.
  68. ^ a b Dietrich, Jorg (2019-11-20). "Suffering from "chemo brain"? There's hope and many things you can do". Harvard Health. Retrieved 2025-11-19.
  69. ^ a b "Symptoms of ME/CFS | Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)". CDC. 9 February 2021.
  70. ^ Kucyi, Aaron; Davis, Karen D. (2015). "The dynamic pain connectome". Trends in Neurosciences. 38 (2): 86–95. doi:10.1016/j.tins.2014.11.006. PMID 25541287. S2CID 745129.
  71. ^ Barkley, Russell A. (2013). Taking Charge of ADHD: The Complete, Authoritative Guide for Parents. Guilford Publications. p. 150. ISBN 978-1-4625-0789-4.
  72. ^ Koralnik, Igor J.; Tyler, Kenneth L. (July 2020). "COVID-19: A Global Threat to the Nervous System". Annals of Neurology. 88 (1): 1–11. doi:10.1002/ana.25807. PMC 7300753. PMID 32506549.
  73. ^ "Long COVID questions and answers". Mayo Clinic. Retrieved 2025-10-04.
  74. ^ a b "What Happens When You Still Have Long COVID Symptoms?". Yale Medicine. Retrieved 2025-10-04.
  75. ^ "Depression and Anxiety in Long COVID: Why Interdisciplinary Treatment Is Needed". Yale Medicine. Retrieved 2025-10-04.
  76. ^ a b Coleon, Anthony; Larrous, Florence; Kergoat, Lauriane; Tichit, Magali; Hardy, David; Obadia, Thomas; Kornobis, Etienne; Bourhy, Hervé; de Melo, Guilherme Dias (2025-07-22). "Hamsters with long COVID present distinct transcriptomic profiles associated with neurodegenerative processes in brainstem". Nature Communications. 16 (1): 6714. Bibcode:2025NatCo..16.6714C. doi:10.1038/s41467-025-62048-7. ISSN 2041-1723. PMC 12283958. PMID 40695836.
  77. ^ a b c Kumar, Puranam Revanth; Shilpa, B.; Jha, Rajesh Kumar (2023-03-31). "Brain disorders: Impact of mild SARS-CoV-2 may shrink several parts of the brain". Neuroscience and Biobehavioral Reviews. 149 105150. doi:10.1016/j.neubiorev.2023.105150. ISSN 1873-7528. PMC 10063523. PMID 37004892.
  78. ^ "Study Shows a Need for Vigilance When Observing Long COVID Symptoms in Younger Children". www.rutgers.edu. Retrieved 2025-09-25.
  79. ^ Douaud, Gwenaëlle; Lee, Soojin; Alfaro-Almagro, Fidel; Arthofer, Christoph; Wang, Chaoyue; McCarthy, Paul; Lange, Frederik; Andersson, Jesper L. R.; Griffanti, Ludovica; Duff, Eugene; Jbabdi, Saad; Taschler, Bernd; Keating, Peter; Winkler, Anderson M.; Collins, Rory (April 2022). "SARS-CoV-2 is associated with changes in brain structure in UK Biobank". Nature. 604 (7907): 697–707. Bibcode:2022Natur.604..697D. doi:10.1038/s41586-022-04569-5. ISSN 1476-4687. PMC 9046077. PMID 35255491.
  80. ^ "Even mild COVID-19 infections change the brain". UK Biobank. 2025-01-19. Retrieved 2025-10-04.
  81. ^ Niesel, David (2022-07-08). "Even a Mild COVID Infection Shrinks the Brain". Medical Discovery News - University of Texas Medical Branch. Retrieved 2025-10-04.
  82. ^ Mehl, Annie (2025-07-30). "Study confirms post-pandemic surge in gut-brain disorders". American Gastroenterological Association. Retrieved 2025-11-29.
  83. ^ Wong, Andrea C.; Devason, Ashwarya S.; Umana, Iboro C.; Cox, Timothy O.; Dohnalová, Lenka; Litichevskiy, Lev; Perla, Jonathan; Lundgren, Patrick; Etwebi, Zienab; Izzo, Luke T.; Kim, Jihee; Tetlak, Monika; Descamps, Hélène C.; Park, Simone L.; Wisser, Stephen (2023-10-26). "Serotonin reduction in post-acute sequelae of viral infection". Cell. 186 (22): 4851–4867.e20. doi:10.1016/j.cell.2023.09.013. ISSN 0092-8674. PMC 11227373. PMID 37848036.
  84. ^ a b c d e Tompa, Rachel (2025-03-06). "The gut-brain connection: What the science says". News Center - Stanford Medicine. Retrieved 2025-11-29.
  85. ^ Yang, Andrew C.; Kern, Fabian; Losada, Patricia M.; Agam, Maayan R.; Maat, Christina A.; Schmartz, Georges P.; Fehlmann, Tobias; Stein, Julian A.; Schaum, Nicholas; Lee, Davis P.; Calcuttawala, Kruti; Vest, Ryan T.; Berdnik, Daniela; Lu, Nannan; Hahn, Oliver (July 2021). "Dysregulation of brain and choroid plexus cell types in severe COVID-19". Nature. 595 (7868): 565–571. Bibcode:2021Natur.595..565Y. doi:10.1038/s41586-021-03710-0. ISSN 1476-4687. PMC 8400927. PMID 34153974.
  86. ^ a b Hu, William T.; Kaluzova, Milota; Dawson, Alice; Sotelo, Victor; Papas, Julia; Lemenze, Alexander; Shu, Carol; Jomartin, Mini; Nayyar, Ashima; Hussain, Sabiha (2024-05-21). "Clinical and CSF single-cell profiling of post-COVID-19 cognitive impairment". Cell Reports Medicine. 5 (5) 101561. doi:10.1016/j.xcrm.2024.101561. ISSN 2666-3791. PMC 11148803. PMID 38744274.
  87. ^ a b c "Rutgers Health Researchers Profile Clinical, Gene and Protein Changes in 'Brain Fog' From Long COVID". www.rutgers.edu. Retrieved 2025-09-25.
  88. ^ a b NJ Spotlight News | Rutgers researchers zero in on long COVID's 'brain fog' | Season 2024. Retrieved 2025-09-25 – via www.pbs.org.
  89. ^ Glass, Jennifer M. (November 2006). "Cognitive dysfunction in fibromyalgia and chronic fatigue syndrome: New trends and future directions". Current Rheumatology Reports. 8 (6): 425–429. doi:10.1007/s11926-006-0036-0. PMID 17092441. S2CID 27103590.
  90. ^ Arnold, Lesley M.; Bennett, Robert M.; Crofford, Leslie J.; Dean, Linda E.; Clauw, Daniel J.; Goldenberg, Don L.; Fitzcharles, Mary-Ann; Paiva, Eduardo S.; Staud, Roland; Sarzi-Puttini, Piercarlo; Buskila, Dan; Macfarlane, Gary J. (June 2019). "AAPT Diagnostic Criteria for Fibromyalgia". The Journal of Pain. 20 (6): 611–628. doi:10.1016/j.jpain.2018.10.008. hdl:2434/632765. PMID 30453109. S2CID 53872511.
  91. ^ Williams, David A; Clauw, Daniel J; Glass, Jennifer M (April 2011). "Perceived Cognitive Dysfunction in Fibromyalgia Syndrome". Journal of Musculoskeletal Pain. 19 (2): 66–75. doi:10.3109/10582452.2011.558989. S2CID 144893303.
  92. ^ [unreliable medical source?] Leavitt, Frank; Katz, Robert S.; Mills, Megan; Heard, Amy R. (April 2002). "Cognitive and Dissociative Manifestations in Fibromyalgia". JCR: Journal of Clinical Rheumatology. 8 (2): 77–84. doi:10.1097/00124743-200204000-00003. PMID 17041327. S2CID 12352666.
  93. ^ a b c d Buskila, Dan; Cohen, Hagit (October 2007). "Comorbidity of fibromyalgia and psychiatric disorders". Current Pain and Headache Reports. 11 (5): 333–338. doi:10.1007/s11916-007-0214-4. PMID 17894922. S2CID 28038437.
  94. ^ Mercado, Francisco; Ferrera, David; Fernandes-Magalhaes, Roberto; Peláez, Irene; Barjola, Paloma (2 March 2022). "Altered Subprocesses of Working Memory in Patients with Fibromyalgia: An Event-Related Potential Study Using N -Back Task". Pain Medicine. 23 (3): 475–487. doi:10.1093/pm/pnab190. PMID 34145889.
  95. ^ a b c Bell, Tyler; Trost, Zina; Buelow, Melissa T.; Clay, Olivio; Younger, Jarred; Moore, David; Crowe, Michael (9 August 2018). "Meta-analysis of cognitive performance in fibromyalgia". Journal of Clinical and Experimental Neuropsychology. 40 (7): 698–714. doi:10.1080/13803395.2017.1422699. PMC 6151134. PMID 29388512.
  96. ^ Bou Khalil, Rami; Khoury, Elie; Richa, Sami (1 September 2018). "The Comorbidity of Fibromyalgia Syndrome and Attention Deficit and Hyperactivity Disorder from a Pathogenic Perspective". Pain Medicine. 19 (9): 1705–1709. doi:10.1093/pm/pny142. PMID 30053155.
  97. ^ Yilmaz, Ertan; Tamam, Lut (24 July 2018). "Attention-deficit hyperactivity disorder and impulsivity in female patients with fibromyalgia". Neuropsychiatric Disease and Treatment. 14: 1883–1889. doi:10.2147/NDT.S159312. PMC 6063452. PMID 30100723.
  98. ^ "Study Suggests Screening Patients with Fibromyalgia Syndrome for ADHD". 28 December 2017.
  99. ^ a b c "The Brain-Gut Connection". Johns Hopkins Medicine. Archived from the original on 2025-10-12. Retrieved 2025-11-28.
  100. ^ a b "Food, Body, Mind". Johns Hopkins Center for Innovative Medicine. Retrieved 2025-11-29.
  101. ^ Powder, Jackie (2021-09-21). "The Gut Microbiome and the Brain | Hopkins Bloomberg Public Health Magazine". Johns Hopkins Bloomberg School of Public Health. Retrieved 2025-11-29.
  102. ^ a b c d e "The Gut-Brain Connection". Cleveland Clinic. 2023-09-20. Retrieved 2025-11-28.
  103. ^ a b Solochek, Lanni (2024-10-08). "Heal Your Gut, Save Your Brain - Mayo Clinic Press". Mayo Clinic Press. Archived from the original on 2025-08-16. Retrieved 2025-11-29.
  104. ^ "The gut-brain connection". Harvard Health. 2023-07-18. Retrieved 2025-11-29.
  105. ^ a b Peppas, Spyros; Pansieri, Claudia; Piovani, Daniele; Danese, Silvio; Peyrin-Biroulet, Laurent; Tsantes, Andreas G.; Brunetta, Enrico; Tsantes, Argirios E.; Bonovas, Stefanos (2021-01-20). "The Brain-Gut Axis: Psychological Functioning and Inflammatory Bowel Diseases". Journal of Clinical Medicine. 10 (3): 377. doi:10.3390/jcm10030377. ISSN 2077-0383. PMC 7863941. PMID 33498197.
  106. ^ a b Rogers, G. B.; Keating, D. J.; Young, R. L.; Wong, M.-L.; Licinio, J.; Wesselingh, S. (2016-04-19). "From gut dysbiosis to altered brain function and mental illness: mechanisms and pathways". Molecular Psychiatry. 21 (6): 738–748. doi:10.1038/mp.2016.50. ISSN 1476-5578. PMC 4879184. PMID 27090305.
  107. ^ Madison, Annelise; Kiecolt-Glaser, Janice K (August 2019). "Stress, depression, diet, and the gut microbiota: human–bacteria interactions at the core of psychoneuroimmunology and nutrition". Current Opinion in Behavioral Sciences. 28: 105–110. doi:10.1016/j.cobeha.2019.01.011. ISSN 2352-1546. PMC 7213601. PMID 32395568.
  108. ^ Ballou, Sarah; Katon, Jesse; Singh, Prashant; Rangan, Vikram; Lee, Ha Neul; McMahon, Courtney; Iturrino, Johanna; Lembo, Anthony; Nee, Judy (2020-04-04). "Chronic Diarrhea and Constipation Are More Common in Depressed Individuals". Clinical Gastroenterology and Hepatology: The Official Clinical Practice Journal of the American Gastroenterological Association. 17 (13): 2696–2703. doi:10.1016/j.cgh.2019.03.046. ISSN 1542-7714. PMC 6776710. PMID 30954714.
  109. ^ Kelly, John R.; Borre, Yuliya; O' Brien, Ciaran; Patterson, Elaine; El Aidy, Sahar; Deane, Jennifer; Kennedy, Paul J.; Beers, Sasja; Scott, Karen; Moloney, Gerard; Hoban, Alan E.; Scott, Lucinda; Fitzgerald, Patrick; Ross, Paul; Stanton, Catherine (November 2016). "Transferring the blues: Depression-associated gut microbiota induces neurobehavioural changes in the rat". Journal of Psychiatric Research. 82: 109–118. doi:10.1016/j.jpsychires.2016.07.019. ISSN 0022-3956. PMID 27491067.
  110. ^ a b "Gut Microbiome". Cleveland Clinic. Retrieved 2025-11-29.
  111. ^ CDC (2025-01-15). "Antibiotic Use and Antimicrobial Resistance Facts". Antibiotic Prescribing and Use. Retrieved 2025-11-29.
  112. ^ Wekking, Ellie M.; Appelhof, Bente C.; Fliers, Eric; Schene, Aart H.; Huyser, Jochanan; Tijssen, Jan G. P.; Wiersinga, Wilmar M. (December 2005). "Cognitive functioning and well-being in euthyroid patients on thyroxine replacement therapy for primary hypothyroidism". European Journal of Endocrinology. 153 (6): 747–753. doi:10.1530/eje.1.02025. ISSN 0804-4643. PMID 16322379.
  113. ^ a b c d Ettleson, Matthew D.; Raine, Ava; Batistuzzo, Alice; Batista, Samuel P.; McAninch, Elizabeth; Teixeira, Maria Cristina T.V.; Jonklaas, Jacqueline; Laiteerapong, Neda; Ribeiro, Miriam O.; Bianco, Antonio C. (March 2022). "Brain Fog in Hypothyroidism: Understanding the Patient's Perspective". Endocrine Practice. 28 (3): 257–264. doi:10.1016/j.eprac.2021.12.003. PMC 8901556. PMID 34890786.
  114. ^ a b c Ebner, Susana (May 2022). "Hypothyroid patients described what brain fog feels like" (PDF). Clinical Thyroidology for the Public - American Thyroid Association. 15 (5): 3–4 – via thyroid.org.
  115. ^ a b c Samuels, Mary H.; Bernstein, Lori J. (July 2022). "Brain Fog in Hypothyroidism: What Is It, How Is It Measured, and What Can Be Done About It". Thyroid: Official Journal of the American Thyroid Association. 32 (7): 752–763. doi:10.1089/thy.2022.0139. ISSN 1557-9077. PMC 9469742. PMID 35414261.
  116. ^ Smith, Jeremy W.; Evans, A Tudor; Costall, B; Smythe, James W. (January 2002). "Thyroid hormones, brain function and cognition: a brief review". Neuroscience & Biobehavioral Reviews. 26 (1): 045–60. doi:10.1016/s0149-7634(01)00037-9. PMID 11835983.
  117. ^ a b Saravanan, P.; Chau, W.-F.; Roberts, N.; Vedhara, K.; Greenwood, R.; Dayan, C. M. (2002). "Psychological well-being in patients on 'adequate' doses of l-thyroxine: results of a large, controlled community-based questionnaire study". Clinical Endocrinology. 57 (5): 577–585. doi:10.1046/j.1365-2265.2002.01654.x. ISSN 1365-2265. PMID 12390330.
  118. ^ Bratton, Robert L.; Whiteside, John W.; Hovan, Michael J.; Engle, Richard L.; Edwards, Frederick D. (May 2008). "Diagnosis and Treatment of Lyme Disease". Mayo Clinic Proceedings. 83 (5): 566–571. doi:10.4065/83.5.566. PMID 18452688.
  119. ^ a b c d "What Is Menopause?". Cleveland Clinic. Archived from the original on 2025-10-04. Retrieved 2025-11-27.
  120. ^ GenderGP (2021-10-21). "Inclusive Language and the Menopause". GenderGP. Retrieved 2025-11-27.
  121. ^ a b c d e f Salamon, Maureen (2022-06-01). "Menopause and brain fog: What's the link?". Harvard Health. Retrieved 2025-11-27.
  122. ^ a b c d e f g Troxel, Wendy M. (2025-04-02). Understanding Meno-Fog: Navigating Brain Fog During Menopause (Report) – via RAND Corporation.
  123. ^ a b c d Petridis, Eileen (2022-01-12). "Severity of Menopause Symptoms Can Affect a Woman's Cognitive Performance" (PDF). The North American Menopause Society.
  124. ^ a b c Shanmugan, Sheila; Epperson, C. Neill (2012-12-14). "Estrogen and the prefrontal cortex: towards a new understanding of estrogen's effects on executive functions in the menopause transition". Human Brain Mapping. 35 (3): 847–865. doi:10.1002/hbm.22218. ISSN 1097-0193. PMC 4104582. PMID 23238908.
  125. ^ a b c Kaur, Mankamal; Kaur, Maninder (2022-01-10). "Is cognitive performance of women sensitive to the severity of menopausal symptoms?". Menopause. 29 (2): 170–177. doi:10.1097/GME.0000000000001910. ISSN 1530-0374. PMID 35013054. Archived from the original on 2025-05-07.
  126. ^ Gallagher, Ashley (2025-11-27). "Severity of menopause symptoms can affect cognitive performance | Contemporary OB/GYN". www.contemporaryobgyn.net. Retrieved 2025-11-27.
  127. ^ Greendale, Gail A.; Wight, Richard G.; Huang, Mei-Hua; Avis, Nancy; Gold, Ellen B.; Joffe, Hadine; Seeman, Teresa; Vuge, Marike; Karlamangla, Arun S. (2010-06-01). "Menopause-associated symptoms and cognitive performance: results from the study of women's health across the nation". American Journal of Epidemiology. 171 (11): 1214–1224. doi:10.1093/aje/kwq067. ISSN 1476-6256. PMC 2915492. PMID 20442205.
  128. ^ a b c Empting LD (2009). "Neurologic and neuropsychiatric syndrome features of mold and mycotoxin exposure". Toxicol Ind Health. 25 (9–10): 577–581. Bibcode:2009ToxIH..25..577E. doi:10.1177/0748233709348393. PMID 19854819. S2CID 27769836.
  129. ^ a b Valtonen V (2017). "Clinical Diagnosis of the Dampness and Mold Hypersensitivity Syndrome: Review of the Literature and Suggested Diagnostic Criteria". Front Immunol. 8 951. doi:10.3389/fimmu.2017.00951. PMC 5554125. PMID 28848553.
  130. ^ a b c Harding CF, Liao D, Persaud R, DeStefano RA, Page KG, Stalbow LL, Roa T, Ford JC, Goman KD, Pytte CL (March 2023). "Differential effects of exposure to toxic or nontoxic mold spores on brain inflammation and Morris water maze performance". Behav Brain Res. 442 114294. doi:10.1016/j.bbr.2023.114294. PMC 10460635. PMID 36638914.
  131. ^ a b Ratnaseelan AM, Tsilioni I, Theoharides TC (June 2018). "Effects of Mycotoxins on Neuropsychiatric Symptoms and Immune Processes". Clin Ther. 40 (6): 903–917. doi:10.1016/j.clinthera.2018.05.004. PMID 29880330.
  132. ^ a b c Harding CF, Pytte CL, Page KG, Ryberg KJ, Normand E, Remigio GJ, DeStefano RA, Morris DB, Voronina J, Lopez A, Stalbow LA, Williams EP, Abreu N (July 2020). "Mold inhalation causes innate immune activation, neural, cognitive and emotional dysfunction". Brain Behav Immun. 87: 218–228. doi:10.1016/j.bbi.2019.11.006. PMC 7231651. PMID 31751617.
  133. ^ a b Viljoen, Margaretha; Claassen, Nicolaas (February 2023). "Pathophysiological aspects of exposure to dampness-associated indoor mould and mycotoxins: A mini-overview". Journal of Hazardous Materials Advances. 9 100228. Bibcode:2023JHzMA...900228V. doi:10.1016/j.hazadv.2022.100228. hdl:2263/95331. ISSN 2772-4166.
  134. ^ Rudert A, Portnoy J (August 2017). "Mold allergy: is it real and what do we do about it?". Expert Rev Clin Immunol. 13 (8): 823–835. doi:10.1080/1744666X.2017.1324298. PMID 28453304. S2CID 4755858.
  135. ^ Borchers AT, Chang C, Eric Gershwin M (June 2017). "Mold and Human Health: a Reality Check". Clin Rev Allergy Immunol. 52 (3): 305–322. doi:10.1007/s12016-017-8601-z. PMID 28299723. S2CID 25709697.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Clouding_of_consciousness&oldid=1326452092"